侧脑室注射腺病毒介导的GDNF基因对帕金森病的保护作用
Neuroprotective effect of adenovirus-mediated GDNF gene in mice models of Parkinsons disease

DOI: 10.6040/j.issn.1671-7554.0.2015.1321

Keywords: 6-四氢吡啶,神经胶质细胞源性神经营养因子,腺病毒,帕金森病,基因治疗,3,1-甲基-4-苯基-1,2,
Glial cell line-derived neurotrophic factor,Adenovirus,Parkinsons disease,Gene therapy,1-methyl-4-henyl-l,2,3,6-tetrahydropyridine

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Stacy M. Medical treatment of Parkinson disease[J]. Neurol Clin, 2009, 27(3): 605-631.
[2]	Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF[J]. Nature, 1996, 380(6571): 252-255.
[3]	Gonzalez-Aparicio R, Flores JA, Fernandez-Espejo E. Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats[J]. ExpNeurol, 2010, 226(1): 136-147.
[4]	Cohen AD, Zigmond MJ, Smith AD, et al. Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration[J]. Brain Res, 2011, 1370(2011): 80-88.
[5]	刘洪梅, 丁艳霞, 王炎强, 等. 表皮生长因子加强胶质细胞系源性神经营养因子对PD 模型大鼠黑质多巴胺能神经元的保护作用[J]. 解剖学杂志, 2011, 34(5): 537-575. LIU Hongmei, DING Yanxia, WANG Yanqiang, et al. EGF enhances the effect of GDNF on protecting dopamine neurons in substantia nigra of Parkinsons disease model in rats[J]. Chinese Journal of Anatomy, 2011, 34(5): 537-575.
[6]	Pardo J, Morel GR, Astiz M, et al. Gene Therapy and Cell Reprogramming for the Aging Brain: Achievements and Promise[J]. Curr Gene Ther, 2014, 14(1): 24-34.
[7]	Dunnett SB, Carter RJ, Watts C, et al. Striatal transplantation in a transgenic mouse model of Huntington's disease[J]. ExpNeurol, 1998, 154(1): 31-40.
[8]	Olsson M, Nikkhah G, Bentlage C, et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test[J]. J Neurosci, 1995, 15(2): 3863-3875.
[9]	Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations[J]. J Neurol Sci, 1973, 20(4): 415-455.
[10]	Biju K, Zhou Q, Li G, et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinsons disease[J]. Molecular Therapy, 2010, 18(8): 1536-1544.
[11]	Lu-Nguyen NB, Broadstock M, Schliesser MG, et al. Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease[J]. Hum Gene Ther, 2014, 25(7): 631-641.
[12]	Wesson DW, Wilson DA. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein(APP)mice[J]. Behav Brain Res, 2011, 216(1): 408-413.
[13]	Littrell OM, Granholm AC, Gerhardt GA, et al. Glial cell-line derived neurotrophic factor(GDNF)replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF[J]. Pharmacol Biochem Behav, 2013, 104(3): 10-19.
[14]	Tereshchenko J, Maddalena A, B？hr M, et al. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinsons disease[J]. Neurobiol Dis, 2014, 65(5): 35-42.
[15]	Lelieveld IM, Müller ML, Bohnen NI, et al. The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative[<sup>11</sup>C] DASB PET imaging study[J]. PLoS One, 2012, 7(7): e40166.
[16]	Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line derived neurotrophic factor for midbrain dopaminergic neurons[J]. Science, 1993, 260(5111): 1130-1132.
[17]	Lu-Nguyen NB, Broadstock M, Schliesser MG, et al. Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinsons disease[J]. Hum Gene Ther, 2014, 25(7): 631-641.
[18]	Ogawa N, Hirose Y, Ohara S, et al. A simple quantitative bradykinesia test in MPTP-treated mice[J]. Res Commun Chem Pathol Pharmacol, 1985, 50(3): 435-441.
[19]	Tomac A, Lindqvist E, Lin LF, et al.Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo[J]. Nature, 1995, 373(6512): 335-339.
[20]	Cash R, Raisman R, Ploska A, et al. High and low affinity[<sup>3</sup>H] imipramine binding sites in control and parkinsonian brains[J]. Eur J Pharmacol, 1985, 117(1): 71-80.

Full-Text